Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hyperhomocysteinaemia.

D J Perry1

  • 1Haemophilia Centre, Department of Haematology, Royal Free & University College Medical School, London, UK.

Bailliere'S Best Practice & Research. Clinical Haematology
|June 17, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Factor X and its deficiency states.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Laboratory monitoring of haemostasis.

Anaesthesia·2014
Same author

Genetic testing in bleeding disorders.

Haemophilia : the official journal of the World Federation of Hemophilia·2014
Same author

Recurrent pregnancy loss and thrombophilia.

The Ceylon medical journal·2014
Same author

Pollen pool heterogeneity in jack pine (Pinus banksiana Lamb.): a problem for estimating outcrossing rates?

TAG. Theoretical and applied genetics. Theoretische und angewandte Genetik·2013
Same journal

Preface

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Index

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Biotechnology: alternatives to human plasma-derived therapeutic proteins.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Red blood cell substitutes.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

The risks of transfusion-transmitted infection: direct estimation and mathematical modelling.

Bailliere's best practice & research. Clinical haematology·2000
Same journal

Will genome detection replace serology in blood screening for microbial agents?

Bailliere's best practice & research. Clinical haematology·2000
See all related articles

Elevated homocysteine levels, often linked to MTHFR gene variants, increase thrombotic disease risk. Dietary supplementation with folate, B6, and B12 effectively lowers homocysteine, a key treatment strategy.

Area of Science:

  • Biochemistry
  • Genetics
  • Vascular Medicine

Background:

  • Homocysteine, a sulfur-containing amino acid, is crucial in metabolic pathways.
  • Inherited disorders like homocystinuria and moderate hyperhomocysteinemia present significant health risks, including vascular disease.
  • While cystathionine-beta-synthase (CBS) defects are known causes, they account for a small percentage of hyperhomocysteinemia cases.

Purpose of the Study:

  • To investigate the role of methylenetetrahydrofolate reductase (MTHFR) gene variants in homocysteine metabolism.
  • To understand the association between MTHFR mutations and vascular disease risk.
  • To evaluate the efficacy of nutritional supplementation in managing elevated homocysteine levels.

Main Methods:

  • Analysis of the C677T mutation in the MTHFR gene.

Related Experiment Videos

  • Assessment of homocysteine levels in relation to folate status and MTHFR genotype.
  • Review of treatment strategies involving vitamin supplementation.

    • Main Results:

    • A thermolabile MTHFR variant (C677T) leads to elevated homocysteine, particularly with low folate levels.
    • This MTHFR mutation is not directly linked to increased vascular disease risk but impacts homocysteine levels.
    • Dietary supplementation with folate, vitamin B6, and vitamin B12 effectively reduces homocysteine.

    Conclusions:

    • Moderate hyperhomocysteinemia, influenced by MTHFR genetics and folate status, is a risk factor for thrombotic events.
    • Vitamin supplementation is the primary treatment for managing elevated homocysteine.
    • Folic acid fortification in foods, like in the USA, can reduce neural tube defects and potentially save lives by lowering homocysteine.